Vicarious Surgical Inc. (ticker: RBOT) reported on its fourth quarter 2023 earnings, detailing progress in the development of its Version 1.0 surgical system and navigating a challenging macroeconomic environment. The company highlighted the expansion of partnerships with major hospital systems, a successful equity follow-on offering that raised $47 million, and regulatory clarity gained through interactions with the FDA.
Despite external headwinds and integration hurdles, Vicarious Surgical managed to complete the build-out of individual subsystems for its V1.0 System and is on track for cadaver testing in spring 2024, with full integration expected by fall. Financially, the company reported a net loss but maintained a strong cash position, ending the year with $98 million in cash and short-term investments.
Key Takeaways
- Vicarious Surgical is transforming its Beta 2 surgical system into the Version 1.0 product.
- The company has expanded partnerships with leading hospital systems, including Intermountain Health.
- Vicarious Surgical raised $47 million through an equity follow-on offering.
- The company received regulatory guidance from the FDA, including the suggestion to include clinical data from patients outside the United States in its de novo submission.
- Vicarious Surgical completed the build-out of individual subsystems for its V1.0 System and expects to conduct cadaver testing in spring 2024.
- The company reported a net loss but ended the year with a strong cash position of $98 million.
Company Outlook
- Vicarious Surgical aims to complete the integration of the V1.0 System by fall 2024.
- The company anticipates conducting cadaver testing in spring 2024 as part of the evaluation process for the system.
- Vicarious Surgical maintains confidence in the potential of its technology and the opportunity to generate value for stakeholders.
Bearish Highlights
- The company faced increased capital costs due to challenging macroeconomic conditions.
- Vicarious Surgical downsized its team twice and reduced future planned expenditures to prioritize capital efficiency.
Bullish Highlights
- Vicarious Surgical's distinctive system architecture and proprietary technology offer potential advantages in surgical robotics.
- The company's partnerships with top healthcare networks provide valuable insights for product refinement and commercial success.
Misses
- Integration hurdles and external headwinds led to an extension of the product development timeline.
Q&A Highlights
- The V1.0 System, once refined after the cadaver lab testing, will be the version Vicarious Surgical intends to take to the FDA for regulatory submission.
- Adjustments and tweaks to the V1.0 System are anticipated throughout the summer and fall of 2024.
Vicarious Surgical's progress in 2023, despite the challenges faced, sets the stage for continued development and eventual commercialization of its surgical robotic system. The company's disciplined spending and strong cash position support its strategic initiatives as it moves towards regulatory submission and market entry.
InvestingPro Insights
Vicarious Surgical Inc. (RBOT) has been navigating a complex financial landscape as it advances its surgical robotic system. The company's focus on maintaining a strong cash position is reflected in the InvestingPro Data, which shows a market cap of $62.98 million and a substantial cash reserve, confirming that the company holds more cash than debt on its balance sheet. This is a critical factor for investors considering the company's ability to fund its operations and development goals.
InvestingPro Tips highlight that analysts have revised their earnings upwards for the upcoming period, suggesting confidence in Vicarious Surgical's prospects despite the fact that the company is not expected to be profitable this year. The revision of earnings forecasts may indicate that market experts see potential in the company's strategic initiatives and partnerships with major hospital systems.
On the flip side, the stock has experienced high price volatility, as evidenced by a 33.31% drop over the last week and a significant 86.91% fall from its 52-week high. This volatility is a crucial consideration for investors looking for stability in their investments.
For readers interested in a deeper dive into Vicarious Surgical's financial health and stock performance, additional InvestingPro Tips are available, which detail aspects such as cash burn rate, gross profit margins, and free cash flow yield. These insights could provide a more comprehensive understanding of the company's financial trajectory.
To explore these additional insights and make informed investment decisions, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. With 14 more InvestingPro Tips available for RBOT, investors can gain a richer perspective on the company's financial standing and market potential.
Full transcript - D8 Holdings (RBOT) Q4 2023:
Operator: Good afternoon, and welcome to Vicarious Surgical's Fourth Quarter 2023 Earnings Conference Call. My name is Matt, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Kaitlyn Brosco with Vicarious Surgical for a few introductory comments.
Kaitlyn Brosco: Thanks, Matt, and thank you all for participating in today's call. Earlier today, Vicarious Surgical released financial results for the three months and full year ended December 31, 2023. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. All forward-looking statements, including, without limitation, those relating to obtaining approval for the Vicarious surgical system and timing for any such approval, our operating trends and future financial performance, expense management, market opportunity and commercialization are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that would cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors set forth in our Securities and Exchange Commission filings, including our most recent Form 10-K and Form 10-Q. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, March 4, 2024. Vicarious Surgical disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. With that, I will turn the call over to Adam Sachs, Chief Executive Officer.
Adam Sachs: Thanks, Kate, and thank you, everyone, for joining us. 2023 was a meaningful year for Vicarious Surgical. We began the process of transforming our Beta 2 surgical system into our Version 1.0 product. With collaboration from our surgeon and hospital system partners, we meticulously shaped the design of our V1.0 System and then turn focus on subsystem build-out and integration in preparation for verification and validation testing. In our V1.0 System design, we incorporated enhancements for a further refined promotion profile and higher image quality with increased system safety, all with the goal of delivering the best products possible for surgeons and hospitals. Considering that only a small fraction, approximately 4%, of soft tissue surgeries currently employ robotics, there is a substantial opportunity to further alleviate the robotics value proposition for patients, surgeons and hospitals. Our distinctive system architecture founded on proprietary decoupled actuator technology not only enables superior capability but also has the potential to streamline training, enhance OR workflow, and to offer compelling economic advantages. Additionally, our architecture facilitates best-in-class visualization, sensing and data collection, all crucial for deploying and integrating automated procedural safeguards into robotic-assisted procedures. We are confident that our innovative approach to surgical robotics, along with its array of distinctive advantages, is the cornerstone to unleashing the complete potential of this field. Throughout 2023, as we continue to press forward on product development, we made meaningful progress, particularly in the sales of each individual subsystem. However, we also encountered external headwinds and met certain integration hurdles. Continuously challenging macroeconomic conditions throughout the year created an opaque market outlook with increased capital costs. Consequently, last year, we made the difficult decision to downsize our team twice and reduce future planned expenditures, prioritizing capital efficiency and ensuring our business is better positioned to navigate such conditions. Furthermore, in the latter part of the year, as we began the V1.0 subsystem integration, we identified certain software and hardware components requiring additional development efforts to ensure system compliance reliability and safety, ahead of entering formal verification and validation process. And while the culmination of these headwinds translated into an extension of time line, I am incredibly proud of how our team adapted and what we were able to achieve nonetheless. To that end, I'd like to touch upon form of our win in 2023 and highlight the milestones we expect to achieve in the quarters ahead. First, we were successful in expanding our foundational partnership with leading hospital systems as we collect feedback on the Vicarious Surgical offering and lay the ground book for commercialization. In the third quarter, we announced our partnership with Intermountain Health, a system of 33 hospitals and 385 clinics spread across the Mountain West region of the United States. This partnership adds to our existing relationships with three of the top health care networks in the country: HCA Healthcare (NYSE:HCA), University Hospitals and Pittsburgh CREATES. Through tapping into their wealth of expertise, these collaborations afford us exclusive insight instrumental in refining our products to precisely match the surgeon that hospital needs to deliver the best possible care for patients, thus ensuring our readiness for commercial success. Second, we raised $47 million through an equity follow-on offering that meaningfully bolstered our balance sheet to support development, clinical and regulatory efforts in the quarters ahead. And finally, through an extensive series of pre-submission meetings with the FDA, we received regulatory clarity. Not only did we receive reassurance that our -- on our path to market, but we were also pleased with the agency suggestion to include clinical data for patients outside the United States in our de novo submission, as OUS clinical data collection will meaningfully facilitate our ability to enroll patients and complete procedures. Thanks to these achievements and our capacity to make the difficult but necessary decisions, we concluded 2023 with the completion of each individual subsystem build for our newly architected V1.0 System, the addition of another major hospital system partnerships of clearly defined regulatory strategies, and a more resilient business structure supported by our strengthened balance sheet. We are excited to drive our momentum into 2024 and execute on our objectives. Within the first month of this year, we made strides in subsystems integration. And today we are excited to affirm that we will conduct cadaver testing this spring as a mean of evaluating our system ahead of final software and hardware refinement, and ultimately complete the integration of our V1.0 System this fall. I'd like to now turn to a few leadership development. Earlier today, we filed an 8-K disclosing David Styka's retirement as Chairman of the Board. David played a pivotal role in our company's accomplishments over the last four years, and we'd like to extend our heartfelt gratitude to him for his guidance and support. With David's departure, we are evaluating our Board composition and potential courses of action. Moreover, I'm thrilled to start 2024 with the appointment of Randy Clark as President of Vicarious Surgical. Randy brings over 20 years of medical device industry experience with a track record of leadership in development, manufacturing and commercialization of innovative solutions. He most recently served as the Global President of the Health Solutions business unit at Flex (NASDAQ:FLEX), and prior to that, spent 15 years at Olympus, progressively assuming leadership roles across various business functions ultimately culminating in his role as President. As we expected, Randy is already proving themselves to be an invaluable leader in asset to Vicarious Surgical as we focus on achieving our 2024 milestone. Now I will turn it over to Bill Kelly to review our financial performance.
William Kelly: Thank you, Adam. Throughout 2023, we proactively adjusted our planned spending to better align with the external environment. We implemented initiatives to streamline resources, optimize spending and restructure the company for maximum efficiency. This included two rounds of downsizing and cost reductions, which we expect to benefit our 2024 expense profile. As a result, total operating expenses for the full year 2023 were $80.7 million, essentially flat compared with the prior year. R&D expenditures for the full year 2023 were $47.6 million, compared to $43.9 million in 2022. General and administrative expenses for the full year were $26.9 million, down compared to $29.7 million in 2022. And full year 2023 sales and marketing expenses of $6.2 million were comparable to the prior year. Adjusted net loss for the full year was $76.3 million, equating to an adjusted net loss of $0.52 per share, as compared to an adjusted net loss of $78.8 million or an adjusted net loss of $0.65 per share for the prior year. GAAP net loss for the full year was $71.1 million, equating to a net loss of $0.49 per share. For a reconciliation of all non-GAAP measures to GAAP, please review our earnings press release. We ended 2023 with approximately $98 million of cash, cash equivalents and short-term investments on our balance sheet. As a result of our disciplined spending during the year, we are pleased to have executed on our full year 2023 cash burn guidance with a burn rate of $63.4 million for the year, in line with our original full year and updated Q3 guidance. Turning to our 2024 outlook. We expect cash burn of approximately $50 million for the full year, in line with our initially provided 2024 cash burn guidance of $40 million to $55 million. With the resources at our disposal and our disciplined fiscal approach, we are confident in our ability to execute on our spring cadaver lab, integrate our Version 1.0 System by this fall, and achieve other important milestones. We look forward to updating you as we progress with our business initiatives in the coming quarters. With that, I will turn the call back to Adam. Adam?
Adam Sachs: Thank you, Bill. 2023 brought about meaningful milestones and strategic decisions that firmly positioned Vicarious Surgical to achieve our 2020 core objectives and advance our long-term vision of delivering innovative surgical robotic solutions to patients, surgeons and hospitals. We maintain steadfast confidence in the potential of our unique technology and the opportunity to generate substantial value for all stakeholders. I'd also like to express my gratitude to all Vicarious Surgical employees for their unwavering hard work and dedication. I eagerly anticipate our continued collaboration and progress throughout 2024. Thank you, everybody, for joining today's call. We're now happy to take any questions. Operator?
Operator: [Operator Instructions] The first question is from the line of Ryan Zimmerman with BTIG. Your line is now open.
Ryan Zimmerman: Good afternoon. Thanks for taking my question. Maybe just to start on the milestones, Adam and Bill. What do you expect to get out of the cadaver lab in the spring? How much can you use for your regulatory submission? And just kind of the expectations there. And then once you get the V1.0 established, again, kind of what's the process from A to B in terms of using that to then get to the next step towards regulatory submission?
Adam Sachs: So thanks so much for the questions, Ryan. First of all, we're really pleased with the progress we've made so far in the V1.0 System. The spring cadaver lab is really about testing that fully integrated V1.0 System. Overall, the purpose of the V1.0 System and the cadaver lab is to prove out that all of that functionality that surgeons and hospitals really loved that was in the Beta 2 prototype is now in our V1.0 product works as effectively, and all of it is being conducted and documented appropriately to be part of our process for the regulatory submission. Then the next step after that, I think was your second question. And that really is about taking any of the challenges that we unearth during this cadaveric process, as well as any bugs resolving those over the rest of the spring, the summer and the fall, into our final V1.0 System.
Ryan Zimmerman: Okay. Got it. Thank you. And well, I guess, just to follow up on that. So just to be clear then, the V1.0 -- is the V1.0 what you're going to the agency with or do you expect to have a V2.0? I just want to make sure I'm clear about kind of that pathway to clearance.
Adam Sachs: It's a fair question. So the V1.0 system is what we intend to take to the agency. But I do want to set expectations that there's a reason that it's not finalized this spring. I do expect to have some things that are going to be tweaked or adjusted overall over the course of the summer and the fall, and we are on track for the fall milestone.
Ryan Zimmerman: Okay. I’ll hop back in queue and probably some others that want to ask questions and if I have others, I'll hop back in. Thanks.
Adam Sachs: Sounds good.
Operator: Thank you for your question. There are currently no further questions registered. [Operator Instructions] There are no additional questions waiting at this time. So I will now end the call. Thank you for joining. You may now disconnect your lines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.